RESEARCH USE ONLY (RUO): This content is intended strictly for educational and laboratory research purposes. Palmitoyl Tripeptide-1 is not approved by the FDA for human consumption, cosmetic application, therapeutic use, or diagnostic procedures. This article does not constitute medical advice.
Palmitoyl Tripeptide-1 Peptide Research: Structure, Matrikine Signaling, and Skin Cell Regeneration
Palmitoyl Tripeptide-1, commonly referred to as Pal-GHK or bio-peptide CL, is a lipopeptide widely studied in skin biology and extracellular matrix (ECM) research. By combining the tripeptide sequence Gly-His-Lys (GHK) with a palmitic acid chain, this compound serves as a synthetic matrikine designed to mimic endogenous cell-signaling fragments released during tissue remodeling.
In laboratory research, Palmitoyl Tripeptide-1 is investigated for its ability to modulate fibroblast activity, collagen synthesis, and cellular repair pathways. Educational updates on peptide research can be found in our peptide research news.
Research Background and Matrikine Signaling Concept
Matrikines are bioactive peptides generated from the controlled degradation of extracellular matrix proteins. These fragments act as feedback messengers, informing fibroblasts of structural damage and initiating repair responses. Palmitoyl Tripeptide-1 is engineered to replicate a specific collagen-derived signal without requiring actual tissue injury.
By imitating residues 853–855 of the type I collagen alpha-2 chain, Palmitoyl Tripeptide-1 creates a biochemical “false signal” that stimulates fibroblasts to increase extracellular matrix production in experimental models.
Chemical Structure and Lipophilic Modification
Palmitoyl Tripeptide-1 is chemically identified as N-(1-oxohexadecyl)glycyl-L-histidyl-L-lysine, with a molecular formula of C38H68N6O5, a molecular weight of approximately 578.8 Da, and CAS number 147732-56-7.
The palmitoyl fatty acid chain enhances lipophilicity, allowing the peptide to interact more efficiently with lipid-rich biological membranes in in vitro and ex vivo skin models. This modification distinguishes Palmitoyl Tripeptide-1 from hydrophilic peptides such as native GHK.
Mechanism of Action in Fibroblast and Skin Cell Models
The primary mechanism of Palmitoyl Tripeptide-1 involves receptor-mediated matrikine signaling. Fibroblasts exposed to this peptide exhibit increased transcription of genes associated with collagen, fibronectin, and glycosaminoglycan synthesis.
Connectivity Map (CMap) analyses of GHK-based peptides suggest modulation of a significant portion of the human genome, including downregulation of pro-inflammatory mediators and upregulation of tissue remodeling pathways.
Extracellular Matrix Synthesis and Structural Support
In vitro fibroblast cultures treated with Palmitoyl Tripeptide-1 demonstrate dose-dependent increases in procollagen type I mRNA expression. Additional studies indicate improved organization of collagen fibers, a critical factor in restoring mechanical integrity within skin tissue models.
Research also suggests an influence on basal keratinocyte adhesion through integrin regulation, reinforcing the dermal–epidermal junction (DEJ) in experimental settings.
Photoprotection and Cellular Stress Response Research
Beyond anabolic signaling, Palmitoyl Tripeptide-1 has been studied for its protective role against environmental stressors. Experimental models indicate modulation of the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), helping preserve collagen integrity following UV exposure.
Studies on keratinocytes suggest reduced oxidative stress and DNA damage in cells pre-treated with Palmitoyl Tripeptide-1 prior to ultraviolet irradiation.
Laboratory Safety Profile and Toxicological Data
Toxicological evaluations conducted under laboratory conditions indicate a favorable safety profile. The Cosmetic Ingredient Review (CIR) Expert Panel reported no evidence of cytotoxicity, sensitization, or irritation at low experimental concentrations.
It is important to note that safety conclusions apply only to controlled research environments and do not imply approval for consumer or medical use.
Research Applications and Regulatory Context
Palmitoyl Tripeptide-1 is classified as a Research Use Only compound. It is not approved by the U.S. Food and Drug Administration for therapeutic or cosmetic application.
Research-grade peptides used in laboratory studies are typically sourced from verified suppliers, such as those listed in our peptide research collection. Accurate experimental planning may also involve tools like a peptide calculator.
Frequently Asked Questions
What is Palmitoyl Tripeptide-1 primarily studied for?
It is studied for its role in matrikine signaling, fibroblast activation, and extracellular matrix regulation in skin and tissue research models.
Is Palmitoyl Tripeptide-1 FDA approved?
No. Palmitoyl Tripeptide-1 is not FDA approved and is designated for research use only.
How does Palmitoyl Tripeptide-1 differ from GHK-Cu?
Palmitoyl Tripeptide-1 is a lipophilic matrikine peptide, while GHK-Cu focuses on copper ion delivery and enzymatic cofactor activity.
Why is a palmitoyl chain added to the peptide?
The palmitoyl chain increases lipophilicity, enhancing membrane interaction and experimental delivery in skin tissue models.
What are the recommended storage conditions?
As a lyophilized peptide, it should be stored at -20°C and protected from moisture and light.
References
- Maquart F.X. et al. Journal of Clinical Investigation, 1993.
- Pickart L., Margolina A. Journal of Biomaterials Science, 2018.
- Cebrián J. et al. International Journal of Cosmetic Science, 2011.
- Huang Y.Y. et al. Photomedicine and Laser Surgery, 2012.
- Cosmetic Ingredient Review (CIR) Expert Panel, Safety Assessment Reports.
- U.S. Food and Drug Administration (FDA).